| Home : December 2019 : December 24, 2019 News : SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma |
SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma |
December 24, 2019
GROSSE POINTE FARMS, Mich., Dec. 23, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted SciTech Development's Investigational New Drug (IND) Application for ST-001 nanoFenretinide, an experimental treatment for T-cell non-Hodgkin's lymphoma (NHL). The FDA...
https://www.prnewswire.com:443/news-releases/scitech-development-llc-announces-fda-acceptance-of-investigational-new-drug-ind-application-for-st-001-nanofenretinide-in-patients-with-t-cell-lymphoma-300978796.html
|
|
|
 Other Stories |
|
|
|
|
|
|
|
|
|
|
|
